Figure 9
SL327 administration at P6, but not at P14, induced long-term deleterious effects, resulting in abnormal behaviors later in adulthood.
(a–c) SL327 administration at P6 induced abnormal behaviors when assessed at 11 weeks of age. (a) No significant differences were observed in total distance traveled over 10 min in the open-field test (control: n = 14, SL327: n = 15). (b) Significant differences were observed in time spent in open arms in the elevated plus-maze (EPM) test (control: n = 13, SL327: n = 14). (c) Short-term spatial working memory was impaired in SL327-treated mice. Percentages of correct alternation responses on the Y-maze test are shown (control: n = 14, SL327: n = 15). (d–f) SL327 administration at P14 induced abnormal behaviors when assessed at 11 weeks of age. (d) No significant differences were observed in total distance traveled in the open-field test (control: n = 12, SL327: n = 14). (e) No significant differences were observed in time spent in open arms in the EPM test (control: n = 12, SL327: n = 14). (f) Short-term spatial working memory was not impaired in SL327-treated mice (control: n = 12, SL327: n = 14). Data are represented as mean ± SEM. **P < 0.01.
